Neurology Today in 5 American Academy of Neurology
-
- Health & Fitness
-
Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today highlights the most noteworthy and newsworthy neurology stories in the issue.
-
Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.
-
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
-
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
-
SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.
-
AI and 911 stroke detection, iatrogenic Alzheimer’s and human growth hormone, seizure dogs and refractory epilepsy
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy.
-
Biomarker for migraine; posterior cortical atrophy gene therapy for neuromuscular disorders
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders.
Customer Reviews
Thank you!
Very Helpful material.